Key result
Multifaceted quality improvement increases the odds of evidence-based therapy prescription by ~130% vs routine practice.
Why the study?
Patients at high cardiovascular risk often fail to receive evidence-based therapies in community practice, necessitating evaluation of interventions to improve prescription rates.
Does a multifaceted quality improvement intervention improve the prescription of evidence-based therapies in patients at high cardiovascular risk?
RCT (n=1,619)
Cluster randomized
Yes
Does a multifaceted quality improvement intervention improve the prescription of evidence-based therapies in patients at high cardiovascular risk?
Odds Ratio: 2.3 (95% CI 1.14–4.65)
Absolute Event Rate: 73.5% vs 58.7%
A multifaceted quality improvement intervention significantly increased the prescription of evidence-based therapies in Brazilian patients at high cardiovascular risk.
Supports adoption of multifaceted QI interventions to boost evidence-based prescribing in high-risk patients; confirms RCT-level efficacy for therapy uptake.
Importance: Studies have found that patients at high cardiovascular risk often fail to receive evidence-based therapies in community practice. Objective: To evaluate whether a multifaceted quality improvement intervention can improve the prescription of evidence-based therapies. Design, Setting, and Participants: In this 2-arm cluster randomized clinical trial, patients with established atherothrombotic disease from 40 public and private outpatient clinics (clusters) in Brazil were studied. Patients were recruited from August 2016 to August 2017, with follow-up to August 2018. Data were analyzed in September 2018. Interventions: Case management, audit and feedback reports, and distribution of educational materials (to health care professionals and patients) vs routine practice. Main Outcomes and Measures: The primary end point was prescription of evidence-based therapies (ie, statins, antiplatelet therapy, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) using the all-or-none approach at 12 months after the intervention period in patients without contraindications. Results: Of the 1619 included patients, 1029 (63.6%) were male, 1327 (82.0%) had coronary artery disease (843 [52.1%] with prior acute myocardial infarction), 355 (21.9%) had prior ischemic stroke or transient ischemic attack, and 197 (12.2%) had peripheral vascular disease, and the mean (SD) age was 65.6 (10.5) years. Among randomized clusters, 30 (75%) were cardiology sites, 6 (15%) were primary care units, and 26 (65%) were teaching institutions. Among eligible patients, those in intervention clusters were more likely to receive a prescription of evidence-based therapies than those in control clusters (73.5% [515 of 701] vs 58.7% [493 of 840]; odds ratio, 2.30; 95% CI, 1.14-4.65). There were no differences between the intervention and control groups with regards to risk factor control (ie, hyperlipidemia, hypertension, or diabetes). Rates of education for smoking cessation were higher among current smokers in the intervention group than in the control group (51.9% [364 of 701] vs 18.2% [153 of 840]; odds ratio, 11.24; 95% CI, 2.20-57.43). The rate of cardiovascular mortality, acute myocardial infarction, and stroke was 2.6% for patients from intervention clusters and 3.4% for those in the control group (hazard ratio, 0.76; 95% CI, 0.43-1.34). Conclusions and Relevance: Among Brazilian patients at high cardiovascular risk, a quality improvement intervention resulted in improved prescription of evidence-based therapies. Trial Registration: ClinicalTrials.gov identifier: NCT02851732.
No takes yet. Share an insight, caveat, or question.
Machline-Carrion et al. (2019) conducted an RCT in Established atherothrombotic disease (n=1,619). Multifaceted quality improvement intervention vs. Routine practice was evaluated on Prescription of evidence-based therapies using the all-or-none approach at 12 months after the intervention period in patients without contraindications (OR 2.30, 95% CI 1.14-4.65). A multifaceted quality improvement intervention increased the prescription of evidence-based therapies compared to routine practice (73.5% vs 58.7%; OR 2.30; 95% CI 1.14-4.65).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: